Search

Displaying results 8011 - 8020 of 8413 in total
  1. Drug

    Plixorafenib

    go.drugbank.com/drugs/DB16038
    Investigational

    PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).

  2. Drug

    RS5441

    go.drugbank.com/drugs/DB33178
    Experimental

    RS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]

  3. Drug

    Human Interleukin 8

    go.drugbank.com/drugs/DB16456
    Investigational

    Interleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).

  4. Drug

    Bifidobacterium Longum Infantis 35624

    go.drugbank.com/drugs/DB17871
    Experimental

    Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]

  5. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  6. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  7. Drug

    Fenpyroximate

    go.drugbank.com/drugs/DB16164
    Investigational

    Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania

  8. Drug

    Zandatrigine

    go.drugbank.com/drugs/DB19051
    Investigational

    Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

  9. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  10. Drug

    Fontolizumab

    go.drugbank.com/drugs/DB05111
    Investigational

    Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.